the higher we can go, the more indications are being opened for Recce.
don't forget this is not only about sepsis, but the tolerability of these compounds in general for the intravenous treatment of any bacterial infection.
once R327 is proven in this phase 1 trial, then there should be no more phase 1 needed for other indications, if the dosages will be within the safety margin already confirmed in this trial. Recce could then jump straight into numerous pivotal trials for other infections.
so no wonder he is excited, this trial (1 and the next pivotal trial) opens up the potential for this compound to be a new broadband antibiotic that can be applied to numerous bacterial infections...penicillin 2.0 in the making
even at this stage, the risk / reward ratio is amazing
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)